Laurus Labs Q3 Review - Vertically Integrated Story Panning Out: ICICI Direct 
An employee holds metformin pills at a Laurus Labs Ltd. pharmaceutical plant in Visakhapatnam, Andhra Pradesh, India. (Photographer: Sara Hylton/Bloomberg)

Laurus Labs Q3 Review - Vertically Integrated Story Panning Out: ICICI Direct 

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Laurus Labs Ltd.’s Q3 revenues grew approximately 76.6% to Rs 1,288 crore amid strong growth across segments driven by 103.5% YoY jump in active pharmaceutical ingredient segment to Rs 731 crore amid strong traction in antiviral APIs to Rs 568 crore (2.65 times YoY) driven by higher volume of first-line products.

Formulations revenue grew 47.2% YoY to Rs 430 crore on the back of higher tender business from low-to-middle-income countries and higher volumes from U.S., Europe.

Contract research and manufacturing services business grew 62.4% YoY to Rs 127 crore.

Ebitda margins improved 1,278 basis points to 33.1% due to better product mix and improved operating leverage.

Click on the attachment to read the full report:

ICICI Direct Laurus Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.